Eversept Partners
Eversept Partners reported 115 stocks worth $1.8B in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are UTHR (8.5%), ABVX (6.6%) and EHC (5.7%). Compared with Q1 2026, the fund opened new positions in CTRE, UNH and COGT, added to UTHR, EHC and ENSG, trimmed ABVX, CLDX and SNDX and sold out of DOC, AVTR and QGEN.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  UTHR United Therapeutics Corp Del | $156M | 8.5% | 288K | +23K (+9%) | 8 of 8 | |
| 2 |  ABVX Abivax SA | $122M | 6.6% | 914K | −21K (−2%) | 4 of 8 | |
| 3 |  EHC Encompass Health Corp | $104M | 5.7% | 1M | +833K (+429%) | 3 of 8 | |
| 4 |  ENSG Ensign Group Inc | $96.5M | 5.3% | 602K | +587K (+3979%) | 2 of 8 | |
| 5 |  VERA Vera Therapeutics Inc | $94.9M | 5.2% | 2.2M | +39K (+2%) | 8 of 8 | |
| 6 |  CLDX Celldex Therapeutics Inc | $66.5M | 3.6% | 1.8M | −2,075 (−0%) | 8 of 8 | |
| 7 |  SNDX Syndax Pharmaceuticals Inc | $61.2M | 3.3% | 2.8M | −87K (−3%) | 8 of 8 | |
| 8 |  BKD Brookdale SR Living Inc | $54.6M | 3.0% | 3.4M | −172K (−5%) | 4 of 8 | |
| 9 |  IONS Ionis Pharmaceuticals Inc | $52.7M | 2.9% | 665K | +33K (+5%) | 8 of 8 | |
| 10 |  NTRA Natera Inc | $47.7M | 2.6% | 176K | −209K (−54%) | 8 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
 DOC Healthpeak Properties Inc | $32.5M | 2M |
 AVTR Avantor Inc | $23.3M | 3M |
 QGEN Qiagen NV Ord Shares | $21.8M | 545K |
 ICLR Icon PLC | $7.6M | 69K |
 AGIO Agios Pharmaceuticals Inc | $6.8M | 200K |
🔒 Free account: see all 21.
Options
valued at the underlying shares
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Eversept Partners 13F FAQ
What does Eversept Partners own?
Eversept Partners reported 115 stocks worth $1.8B in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are UTHR (8.5%), ABVX (6.6%) and EHC (5.7%). The table above lists every position in the filing (the top 10 without an account).
What did Eversept Partners buy and sell in Q2 2026?
Compared with Q1 2026: 32 new positions, 37 added to, 39 trimmed and 21 sold out. New positions include CTRE, UNH and COGT. It sold all of DOC, AVTR and QGEN.
When will Eversept Partners file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Eversept Partners's portfolio worth?
The Q2 2026 filing reports $1.8B in US stocks ($1.9B including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.